Skip to main content
. 2022 Aug 16;2(4):395–411. doi: 10.1016/j.jacasi.2022.05.005

Table 1.

Asian Countries/Territories Included in Asian Subanalyses of Major NOAC Trials

First Author Trial Name (N) Drug Countries/Territories Included
Hori et al27 RE-LY (2,782) Dabigatran China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand, India
Wong et al28 ROCKET AF (932) Rivaroxaban China, South Korea, Taiwan, Hong Kong
Goto et al29 ARISTOTLE (1,993) Apixaban China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia
Yamashita et al30 ENGAGE-AF (1,943) Edoxaban China, Japan, South Korea, Taiwan

ARISTOTLE = Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ENGAGE-AF = Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation; RE-LY = Randomized Evaluation of Long-Term Anticoagulation Therapy; ROCKET AF = Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation.